Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
作者： Paul Y Kwo , Eric J Lawitz , Jonathan McCone , Eugene R Schiff , John M Vierling
DOI: 10.1016/S0140-6736(10)60934-8
关键词:
摘要: Findings Patients in all four boceprevir groups had higher rates of SVR than did the control group (58/107 [54%, 95% CI 44–64], p=0·013 for PRB28; 58/103 [56%, 44–66], p=0·005 PR4/PRB24; 69/103 [67%, 57–76], p<0·0001 PRB48; and 77/103 [75%, 65–83], PR4/PRB44; vs 39/104 [38%, 28–48] PR48 control). Lowdose ribavirin was associated with a high rate viral breakthrough (16/59 [27%]), relapse (six 27 [22%]) similar to (12/51 [24%]). Boceprevir-based anaemia (227/416 [55%] 35/104 [34%]) dysgeusia (111/416 [27%] nine 104 [9%]) group.
cabdirect.org
elsevier.com
sci-hub.se 参考文章(31)
X TONG, R CHASE, A SKELTON, T CHEN, J WRIGHTMINOGUE, B MALCOLM, Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Research. ,vol. 70, pp. 28- 38 ,(2006) , 10.1016/J.ANTIVIRAL.2005.12.003
Thierry Poynard, John McHutchison, Michael Manns, Christian Trepo, Karen Lindsay, Zachary Goodman, Mei–Hsiu Ling, Janice Albrecht, PEG-fibrosis project group, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. ,vol. 122, pp. 1303- 1313 ,(2002) , 10.1053/GAST.2002.33023
Elizabeth C. Verna, Robert S. Brown, Hepatitis C Virus and Liver Transplantation Clinics in Liver Disease. ,vol. 10, pp. 919- 940 ,(2006) , 10.1016/J.CLD.2006.08.012
Stefan Zeuzem, Maria Buti, Peter Ferenci, Jan Sperl, Yves Horsmans, Janusz Cianciara, Endre Ibranyi, Ola Weiland, Stephanie Noviello, Clifford Brass, Janice Albrecht, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia Journal of Hepatology. ,vol. 44, pp. 97- 103 ,(2006) , 10.1016/J.JHEP.2005.10.003
Barbara H. McGovern, Barham K. Abu Dayyeh, Raymond T. Chung, Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection† Hepatology. ,vol. 48, pp. 1700- 1712 ,(2008) , 10.1002/HEP.22563
Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, Tobias Goeser, Jean-Pierre Bronowicki, Marc Bourlière, Shahin Gharakhanian, Leif Bengtsson, Lindsay McNair, Shelley George, Tara Kieffer, Ann Kwong, Robert S. Kauffman, John Alam, Jean-Michel Pawlotsky, Stefan Zeuzem, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine. ,vol. 360, pp. 1839- 1850 ,(2009) , 10.1056/NEJMOA0807650
Andrew J. Muir, Jeffrey D. Bornstein, Paul G. Killenberg, Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. The New England Journal of Medicine. ,vol. 350, pp. 2265- 2271 ,(2004) , 10.1056/NEJMOA032502
M. Sulkowski, M. Shiffman, N. Afdhal, R. Reddy, J. McCone, W. Lee, S. Herrine, S. Harrison, W. Deng, C. Brass, K. Koury, S. Noviello, J. Albrecht, J. McHutchison, 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)60128-8
Gary L Davis, John B Wong, John G McHutchison, Michael P Manns, Joann Harvey, Janice Albrecht, None, Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C Hepatology. ,vol. 38, pp. 645- 652 ,(2003) , 10.1053/JHEP.2003.50364
Christoph Sarrazin, Tara L. Kieffer, Doug Bartels, Brian Hanzelka, Ute Müh, Martin Welker, Dennis Wincheringer, Yi Zhou, Hui–May Chu, Chao Lin, Christine Weegink, Henk Reesink, Stefan Zeuzem, Ann D. Kwong, Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir Gastroenterology. ,vol. 132, pp. 1767- 1777 ,(2007) , 10.1053/J.GASTRO.2007.02.037